Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITI-001 in IBS-D
NCT07238790Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MITI-001 in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Stanford University. Primary endpoint: Safety of MITI-001 at 90 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
MITI-001
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT07238790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238790.